Agmatine, an endogenous guanidine amine, has been shown to produce antidepressant-like effects in animal studies. This study investigated the effects of the combined administration of agmatine with either conventional monoaminergic antidepressants or the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 in the tail suspension test (TST) in mice. The aim was to evaluate the extent of the antidepressant synergism by examining the ability of a fixed dose of agmatine to shift the antidepressant potency of fluoxetine, imipramine, bupropion and MK-801. A sub-effective dose of agmatine (0.0001 mg/kg, p.o.) significantly increased the potency by which fluoxetine, imipramine, bupropion and MK-801 decreased immobility time in the TST by 2-fold (fluoxetine), 10-fold (imipramine and bupropion) and 100-fold (MK-801). Combined with previous evidence indicating a role of monoaminergic systems in the effect of agmatine, the current data suggest that agmatine may modulate monoaminergic neurotransmission and augment the activity of conventional antidepressants. Moreover, this study found that agmatine substantially augmented the antidepressant-like effect of MK-801, reinforcing the notion that this compound modulates NMDA receptor activation. These preclinical data may stimulate future clinical studies testing the effects of augmentation therapy with agmatine for the management of depressive disorders.
Introduction
Depression, a relatively common and serious psychiatric disorder, is a leading cause of disability worldwide, affecting up to 15% of the population at least once in their lifetime (Kiecolt-Glaser and Glaser, 2002) . Current antidepressants are generally safe and effective; treatments though, have several drawbacks. Antidepressants must be given for at least several weeks until patients experience beneficial effects. In addition, side effects are still a serious problem even with the newer medications (Berton and Nestler, 2006) and only 50% of all patients demonstrate complete remission, although many (up to 80%) show partial responses to these drugs (Nestler et al., 2002) . Therefore, there is still a great need for faster acting, safer and more effective treatments for depression (Berton and Nestler, 2006) . Regarding this issue, augmentation therapy has emerged as a therapeutic option for treating refractory depressive patients and to reduce side effects (Rogoz, 2013; Stryjer et al., 2014) .
Numerous antidepressant compounds are now available, presumably acting via different mechanisms including serotonergic, noradrenergic and/or dopaminergic systems (Elhwuegi, 2004) . Several lines of evidence indicate that alterations in serotonergic and noradrenergic neurotransmission are implicated in the pathophysiology of depression (Elhwuegi, 2004) . In addition, the dopaminergic system is also an important target implicated in the regulation of mood disorders (Dailly et al., 2004) and studies suggest an involvement of this system in antidepressant-like responses in preclinical models of depression (D'Aquila et al., 2000) .
Furthermore, several basic and clinical studies indicate that the glutamatergic system is widely implicated in the pathophysiology of depression. Preclinical research has suggested that reducing N-methyl-Daspartate (NMDA) receptor function leads to antidepressant-like effects in several animal models of depression and prevents stress-induced alterations in hippocampal neuronal morphology (Skolnick, 1999) . Chronic treatment with antidepressants downregulates NMDA receptors and reduces glutamate release through presynaptic mechanisms (Paul and Skolnick, 2003; Sanacora et al., 2003) . Additionally, high levels of serum glutamate were found in depressed patients (Hashimoto et al., 2007; Mitani et al., 2006 ) and a positive relationship between these levels and the severity of depressive symptoms has been shown (Mitani et al., 2006) .
During the past decade both preclinical and clinical studies (Skolnick, 1999; Skolnick et al., 2001) have indicated that glutamatergic neurotransmission represents a key target for the discovery of antidepressants that may have a more rapid onset (Berman et al., 2000; Papp and Moryl, 1994) than monoamine-based therapies. The majority of these studies have focused on the NMDA subtype of glutamate receptor. Of note, sub-anesthetic doses of intravenously infused ketamine, a noncompetitive NMDA receptor antagonist that possesses psychotomimetic properties, produce a rapid antidepressant effect on individuals with treatment-resistant depression (Berman et al., 2000; Zarate et al., 2006) . This finding suggests that depressive symptoms can be improved by modulating the glutamatergic system.
Agmatine, an endogenous neuromodulator synthesized by decarboxylation of L-arginine (Piletz et al., 1995; Reis and Regunathan, 2000) , has gained attention as a putative antidepressant agent (Y.F. Li et al., 2003; Zomkowski et al., 2002; Zomkowski et al., 2004) and became popular for its therapeutic potential for several diseases and apparent lack of toxicity (Piletz et al., 2013; Wu et al., 2008) . Our group has previously demonstrated that agmatine produces an antidepressant-like effect in the forced swimming test (FST) and in the tail suspension test (TST) in mice, through a mechanism that involves the L-arginine-nitric oxide pathway and α 2 -adrenoceptors (Zomkowski et al., 2002) , as well as modulation of the serotonergic system and inhibition of NMDA receptors (Zomkowski et al., 2004) . Agmatine has also been reported to prevent neurotoxicity produced by glutamate and NMDA in PC12 cells and neuronal cultures of rat cortex (Zhu et al., 2003) and cerebellum (Gilad et al., 1996; Olmos et al., 1999) .
Taking into account that agmatine may modulate monoaminergic and glutamatergic systems, and the relevance of augmentation therapy to improve the treatment of depression (Conway et al., 2014; DeBattista, 2006) this study aimed at investigating the extent of the antidepressant synergism elicited by the combined administration of agmatine with either conventional antidepressants or the NMDA receptor antagonist MK-801.
Material and methods

Animals
Adult female Swiss mice (30-35 g) were maintained at 20-22°C with free access to water and food, under a 12/12 h light-dark cycle (lights on at 07:00 h). The cages were placed in the experimental room for 24 h before the test for acclimatization. All manipulations were carried out between 9:00 and 17:00 h. Each animal was subjected to experimental manipulations only once (N = 7-8 animals per group). All procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All experimental protocols were approved by the Institutional Ethics Committee and all efforts were made to minimize animal suffering.
Drugs and treatment
The following drugs were used: agmatine, fluoxetine, imipramine, bupropion and MK-801. All drugs were obtained from Sigma Chemical Co. (St. Louis, U.S.A.), except bupropion, which was obtained from Libbs Farmaceutica Ltda. (Brazil). Drugs were dissolved in distilled water and appropriate vehicle treated groups were assessed simultaneously. The drugs were administered orally (p.o.) by gavage in a constant volume of 10 ml/kg body weight.
Experimental procedure
Mice were pretreated with a range of sub-effective doses of either fluoxetine (1, 2.5 and 5 mg/kg, p.o.; a selective serotonin reuptake inhibitor), imipramine (0.01, 0.05 and 0.1 mg/kg, p.o.; a tricyclic antidepressant), bupropion (0.1, 0.5 and 1 mg/kg, p.o.; dopamine reuptake inhibitor with subtle activity on noradrenergic reuptake), or MK-801 (0.0001, 0.0005 and 0.001 mg/kg, p.o.; noncompetitive NMDA receptor antagonist) and immediately after, a sub-effective dose of either agmatine (0.0001 mg/kg p.o.) or vehicle was administered. After 60 min, the animals were subjected to behavioral testing.
Behavioral tests 2.4.1. Tail suspension test
The total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. (1985) . Briefly, mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Immobility time was recorded during a 6 min period (Freitas et al., 2010; Moretti et al., 2011) .
Open-field test
To assess the effects of agmatine on locomotor activity, mice were evaluated in the open-field paradigm as previously described (Kaster et al., 2005; Rodrigues et al., 1996; Steru et al., 1985) . The apparatus consisted of a wooden box measuring 40 × 60 × 50 cm. The floor of the arena was divided into 12 equal squares. The number of squares crossed with all paws (crossing) was counted during a 6 min session. The apparatus was cleaned with a solution of 10% ethanol between trials to eliminate animal clues.
Statistical analysis
Dose-effect functions were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's test for post-hoc comparison of effects in vehicle-treated animals compared to effects of each drug dose. The minimum effective dose (MED; the lowest dose of drug producing a statistically significant change as compared to the control group) was determined from this analysis. Shifts in dose-response curves were conservatively evaluated by estimating the relative potency (B coefficient) using simple linear regression. A positive value of B coefficient indicates a positive correlation, and a negative value as obtained in this study, means that the increase on the doses is associated with decreases in the immobility time of animals. This analysis was performed based on a paper describing a synergism between glutamate and biogenic amine based agents (X. Li et al., 2003) . The correlations were significant if p b 0.05. The magnitude of the decrease in immobility time for each 1 mg per kilogram of dose increase (agmatine + antidepressants) is indicated by the B coefficient. Shifts in the dose-effect curves were considered significant when the 95% confidence limits for the B coefficient did not include 1.0. Table 1 summarizes the effects of agmatine, conventional antidepressants and MK-801 on immobility time in the TST. After a dose-response curve, all compounds examined reduced immobility time in a dose-dependent manner according to the following rank order (from the most potent to the least potent): agmatine N MK-801 N fluoxetine = bupropion N imipramine. MED, the minimal effective dose that decreases immobility time in the TST, was calculated for each compound and is indicated in Table 1 .
Results
Once the MED values were established, agmatine was administered at a sub-effective dose (that does not reduce the immobility time in the TST; ten times less than MED, 0.001 mg/kg) in combination with a range of doses of conventional antidepressants or MK-801 (Table 2) . In these experiments, the MED of antidepressants was reduced between 2-fold (fluoxetine) to as high as 100-fold (MK-801) by combination with agmatine.
The comparisons between the immobility time in the TST of mice treated with a dose-range of bupropion, imipramine, fluoxetine and MK-801 alone or in the presence of a sub-effective dose of agmatine are shown in Fig. 1 (A, B, C, D) . The graphs illustrate the increase in antidepressant potency of fluoxetine, imipramine, bupropion and MK-801 in the TST by agmatine.
The correlation between the reduction of immobility time afforded by antidepressants and the dose used was estimated. Table 3 shows that no significant correlation between administration of sub-effective doses of antidepressants and the reduction in immobility time of animals was observed. Table 4 summarizes the correlation between immobility time of animals and different sub-effective doses of antidepressants used in combination with a sub-effective dose of agmatine. These results show that each increment of 1 mg/kg in the doses of bupropion or fluoxetine reduces the immobility time of animals by 44 s and 11 s, respectively. In addition, when the dose of imipramine augments 0.1 mg/kg, there is a reduction of 61 s in the immobility time of animals. Finally, each 0.001 mg/kg of increase in the dose of MK-801 reduces the immobility time of animals by 54 s.
The graphs shown in Fig. 2 A-D illustrate the correlation between immobility time of animals with the different sub-effective doses of antidepressants or MK-801 (alone or in combination with agmatine administered at a sub-effective dose).
The administration of conventional antidepressants, MK-801 or agmatine, either alone or in combination, did not affect the ambulation in the open-field test (data not shown).
Discussion
As a result of evidence accumulated during the past decade, augmentation therapy is becoming a common and recommended strategy to treat patients that do not achieve an adequate response with first-line antidepressant monotherapy, since it often shows better efficacy (Chang et al., 2013; Hori and Kunugi, 2012; Kessler et al., 2003; Patkar and Pae, 2013) . From this perspective, preclinical studies investigating combination approaches may provide a neuropharmacological A dose of agmatine 10 times lower than the MED (0.001 mg/kg) was given in conjunction with a range of doses of the antidepressant compounds and an MED in the presence of the agmatine was calculated by ANOVA followed by Dunnett's test. The fold-decrease compares the MED of the drug combination (this table) to the MED of the antidepressants alone (Table 1 ). All compounds were administered (p.o.) 60 min prior to behavioral tests. Between 7 and 8 mice were evaluated at each dose. basis to support the clinical use of these combinations. Therefore the present study was designed to establish the magnitude of the antidepressant synergism elicited by a fixed sub-effective dose of agmatine to shift the antidepressant potency of conventional antidepressants as well as MK-801.
In the first set of experiments, this study showed that conventional antidepressants (fluoxetine, imipramine and bupropion), MK-801 or agmatine administered alone by oral route reduced the immobility time in the TST in a dose-dependent manner. Thereby, the minimal effective dose (MED) of these compounds in the TST was determined. The MED values are in agreement with previous findings from our group (Cunha et al., 2008; Neis et al., 2014) . Of note, the MED value of MK-801 is much lower than those of the antidepressants tested.
In a second set of experiments, agmatine administered at a subeffective dose (ten times less than MED, 0.001 mg/kg) in combination with sub-effective doses of conventional antidepressants, elicited a synergistic antidepressant-like effect with all the antidepressants tested. The magnitude of this synergistic effect was not uniform, since it reduced the MED of these agents between 2 (fluoxetine) and 10-fold (imipramine and bupropion). This study extends previous findings that showed a synergic antidepressant like-effect of agmatine with fluoxetine Taksande et al., 2009; Zomkowski et al., 2004) , imipramine and bupropion (Kotagale et al., 2013; Neis et al., 2014) . In agreement with these results, several studies have shown that the antidepressant-like effect of agmatine is mediated by serotonergic (Zomkowski et al., 2004) and noradrenergic systems (Onal et al., 2003) . Moreover, it was reported that plasma levels of agmatine were depleted in depressive patients and treatment with bupropion normalized this effect (Halaris et al., 1999) . In addition, compounds with potential antidepressant-like effect can also produce a synergic effect when administered with conventional antidepressants (Cunha et al., 2008; Manosso et al., 2013; Reus et al., 2011) .
It remains to be investigated whether the combined administration of agmatine with conventional antidepressants to depressive patients could also cause a synergic antidepressant effect. It may allow the intake of lower doses of antidepressants, diminishing the side effects and therefore having a beneficial impact in the quality of life. Besides having a synergic effect with conventional antidepressants, a sub-effective dose of agmatine administered in combination with a range of sub-effective doses of MK-801 was also able to reduce the MED of MK-801 by 100-fold. Although previous studies have shown that agmatine may enhance the antidepressant-like effect of MK-801 in the TST and in the FST (Zeidan et al., 2007) , no previous study had reported the potency of this synergism. Reinforcing the notion that the mechanism underlying the antidepressant-like effect of agmatine is dependent on the inhibition of NMDA receptors, previous studies have reported that agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal (Olmos et al., 1999; Wang et al., 2006) and cortical (Gilad et al., 1996; Zhu et al., 2003) neurons. In addition, agmatine reverses the NMDA receptor-induced intracellular Ca 2+ overload and the decrease of monoamines (including norepinephrine, epinephrine and dopamine) content in PC12 cells (Y.F. Li et al., 2003) . Accordingly, NMDA receptor antagonists, including MK-801, are known to produce antidepressant-like effects in various animal models of depression (Mantovani et al., 2003; Sanacora et al., 2008; Skolnick, 1999) , and the combination of traditional antidepressant drugs and NMDA receptor antagonists was reported to produce enhanced antidepressant effects in the FST (Rogoz et al., 2002) . To our knowledge, there is currently no data with regards to the pharmacokinetic interaction between agmatine and bupropion, imipramine, fluoxetine, or MK-801. Agmatine could increase the concentrations of these compounds in the central nervous system and thereby enhance the antidepressant potency. Therefore, it remains to be established whether these pharmacokinetic interactions may account for the observed behavioral responses in the TST in mice treated with agmatine in combination with these drugs.
It is interesting to note that a sub-effective dose of agmatine was able to decrease the MED of MK-801 by a greater magnitude (100-fold) when compared to the MED of antidepressants. This difference between the synergistic effects obtained with antidepressants and with MK-801 may be due to a higher affinity of agmatine with NMDA receptors than with monoaminergic systems. Indeed, the downstream consequences of inhibition of NMDA receptors may affect one or more intracellular pathways implicated in antidepressant responses. In agreement, agmatine was shown to generate a voltage-and concentrationdependent blockage of the NMDA receptor channel in rat hippocampal neurons by interacting with a site located within the NMDA channel pore, and the guanidine group of agmatine has been identified as the responsible moiety for the blockage of the NMDA receptor channel (Roberts et al., 2005; Wang et al., 2006; Yang and Reis, 1999) . MK-801 preferentially binds to the activated NMDA receptor complex interacting with a site located within the NMDA channel (Javitt and Zukin, 1989) , but its off-kinetics are effectively non-voltage-dependent as a consequence of slow channel binding kinetics.
Interestingly, the doses of agmatine required to produce antidepressant-like effects that were used in the present study are extremely low when compared to other studies, most of them using systemic (at concentrations of 5-80 mg/kg, i.p.) as opposed to oral (Y.F. Li et al., 2003; Taksande et al., 2009) administration. Higher doses of agmatine are also required to observe other pharmacological effects, such as anxiolytic, anticonvulsant and antinociceptive properties (Demehri et al., 2003; Gong et al., 2006; Santos et al., 2005) . Besides differences in the administration route, this discrepancy may also be attributed to differences in the mouse strains used and/or sex differences. Despite the aforementioned differences, the doses of agmatine The correlation between sub-effective doses of antidepressants and the immobility time in the TST was done with range of sub-effective doses of the antidepressant compounds and univariated analysis by linear regression. All compounds were administered (p.o.) 60 min prior to testing. Between 7 and 8 mice were evaluated at each dose. used in the present work are in agreement with previous findings from our group, showing an antidepressant-like effect of this compound at very low doses when administered by oral route in female Swiss mice Neis et al., 2014) . Of note, a recent study showed that agmatine had antidepressant effects in three depressive patients, apparently via a serotoninergicindependent mechanism, since its effects were not reversed by parachlorophenylalanine (PCPA), an inhibitor of serotonin synthesis (Shopsin, 2013) . Moreover, it is important to emphasize that clinical trials have shown that agmatine does not have adverse effects (Keynan et al., 2010) . Thus, the possibility of considering agmatine as a monotherapy for the treatment of depression is feasible.
Considering that the interest in targeting the glutamatergic system for the treatment of depressive disorders has grown rapidly in recent years (Maeng et al., 2008; Sanacora et al., 2008) , the results presented in this study may provide the background for further investigating the antidepressant effects of agmatine for the management of depression. Moreover, augmentation therapy with agmatine may provide a safer therapeutic approach by reducing the side effects. Finally, these results may inspire new lines of preclinical research to explore NMDA receptor modulators to further optimize the treatment of depression.
Conclusion
The present results indicate the ability of agmatine to enhance the antidepressant-like effects of conventional antidepressants, and of particular interest, MK-801, suggesting that this amine may augment the activity and perhaps the onset of the therapeutic effects of these compounds. Taken into account the relevance of modulating the glutamatergic system for the management of depressive disorders, the data presented here may be of therapeutic relevance.
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